AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04369313 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: early cord clamping
Description: umbilical cord clamping within 15 seconds after birth
Study NCT00292942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Artesunate
Description: Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
Study NCT00292942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
Study NCT04468581 — intervention group
Intervention type: BEHAVIORAL
Intervention: Use of mobile application
Description: Use of the TraceTogether mobile application during the COVID-19 period
Study NCT05464797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytokines level in pulpal blood.
Description: Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
Study NCT05464797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cytokines level in pulpal blood.
Description: Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
Study NCT05515003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized patient education
Description: In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes.
Study NCT01599156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
Study NCT00768794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidophilus
Description: Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
Study NCT00768794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidolphilus
Description: The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
Study NCT00600678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)
Description: Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
Study NCT03354091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Flex 2
Description: Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
Study NCT00757588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin, 5 mg + insulin
Description: Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
Study NCT00757588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + insulin
Description: Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
Study NCT02703051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study NCT02703051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Study NCT02703051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT02703051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Study NCT02703051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Infusion
Study NCT00241228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venovenous haemofiltration (renal replacement therapy)
Description: High Volume ultra filtration (70 ml/kg/h)
Study NCT00241228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venovenous haemofiltration (renal replacement therapy)
Description: Conventional Volume (35 ml/kg/h)
Study NCT02307708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8° incline shoe
Description: Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction).
Study NCT02307708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesitherapy
Description: Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
Study NCT04273334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NEB
Description: 68Ga-NEB were injected into the patients before the PET/CT scans
Study NCT02885688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Nutrition
Description: Participants receive liquid nutrition by vein non-stop for up to 7 days.
Study NCT02885688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin Drip
Description: Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU.
Study NCT02885688 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin Drip
Description: Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU.
Study NCT02643108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Description: When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
Study NCT04480320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
Study NCT04480320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pericapsular nerve group block
Description: Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
Study NCT02995356 — intervention group
Intervention type: OTHER
Intervention: Collecting cervical liquid and sera samples
Study NCT04376307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal flow anesthesia
Description: Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
Study NCT03803189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care plus eToolkit
Description: The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
Study NCT01152658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
Study NCT01152658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NACL
Description: Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT02872116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT04349072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Mavacamten Capsules Other names: MYK-461
Study NCT04349072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05189743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin transplantation to heal burn injuries
Description: The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest.
Study NCT04131023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breezing Metabolic Rate Tracking
Description: Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
Study NCT01101399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Study NCT04389359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
Study NCT02898454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT02898454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT02898454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT02898454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal
Study NCT02898454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal
Study NCT02735967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
Study NCT02735967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
Study NCT02735967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: diadynamic current
Description: Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
Study NCT02735967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diadynamic current
Description: Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
Study NCT00148902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib
Study NCT00148902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel
Study NCT01256268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
Study NCT01256268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
Study NCT01256268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
Study NCT02952365 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tissue sealant
Description: Application of tissue sealant on eyes undergoing LASIK enhancement
Study NCT03844399 — intervention group
Intervention type: DEVICE
Intervention: Ablation
Description: The medical device will passively record image data during the standard care ablation
Study NCT03844399 — intervention group
Intervention type: DEVICE
Intervention: Biopsy
Description: The medical device will passively record image data during the standard care biopsy
Study NCT01283555 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir
Description: Delivered using prefilled and user-filled applicator
Study NCT01283555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Delivered using prefilled and user-filled applicator
Study NCT03318549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Visual Performance tests
Description: Participants came to the clinic in person for 2 hours for visual performance tests once every 6 months for up to 5 years. These tests included virtual reality tests and tests on a computer screen to investigate performance during simulated daily life activities, such as driving, situations of low contrast and glare.
Study NCT03318549 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Brain-computer interface
Description: The brain-computer interface (BCI) consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle. The test is done in person and may take up to 30 minutes, once every 6 months for up to 5 years.
Study NCT02657889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Study NCT02657889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT00392392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: ABI-007
Study NCT00392392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT00392392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study NCT01820286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Study NCT01820286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recollection intervention
Study NCT02416999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-low dose Bevacizumab
Study NCT02416999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT04604041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
Description: All groups will not have the same intervention. Interventions are listed and numbered for each group.
Study NCT00788307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-CMV-NIS
Study NCT00788307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liothyronine sodium
Study NCT00788307 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00788307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00788307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131
Study NCT01894607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Intraoperative Ultrasound
Description: During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.